Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Lung Cancer Therapeutics Market 2016: Chemotherapy, Taxotere, Hycamtin, Navelbine, Gemzar

Thursday, October 13, 2016 0:06
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Latest industry research report on Lung cancer Therapeutics is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs’ ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss.

Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.

Request a Brochure of This Report, here:

Global lung cancer therapeutics market shows promising CAGR due to increasing population of lung cancer and it is expected that trend would continue with the same momentum. Advanced stages of lung cancer still show high unmet need for diagnosis and treatment. The potential drivers for lung cancer therapeutic market include tobacco smoking (including passive smoke), aged population and lifestyle factors.

Additionally, innovative and targeted drug delivery to lung is found to be a major driver for the growth of this market. However, high unmet need for diagnosis, availability of large number of generic forms of major drugs and limited treatment options are the critical restrains to the global lung cancer therapeutics market. Chemotherapy and radiation therapy poses bigger challenge of adverse effect. Hence, big players in this market have to focus on innovative therapies and safer therapeutics.

Inquiry To Buy Report:

Global Lung Cancer Therapeutics Market by Therapeutics

The global lung cancer therapeutics market is segmented by therapy into five broad categories, namely Chemotherapy, Targeted therapy and Pipeline drugs, Surgery and Radiotherapy. NSCLC contributes for high prevalence than SCLC. Avastin by Roche was the blockbuster drug for the past few years that accounted for major percentage of the total sale. Other top brands of therapeutics include Gemzar, Taxotere and Tarceva and used for NSCLC. For SCLC treatment, ifosfamide or etoposide is combined with platinum analog and forms standard chemotherapeutic regimen. Many a times, Radiotherapy in combination with chemotherapy, is used as better option before surgery to increase the effectiveness of the treatment. Key Challenge in successful pipeline therapy includes its integration with existing therapy or its superiority over existing therapy.

Competitive Landscape

The leading companies in global lung cancer therapeutics market include Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Pfizer, and Agennix AG. Currently, Roche, Agennix AG and Pfizer are ruling the market for global lung cancer therapeutics and expected to capture half of the market share during the forecast period. Decline in sales value of AstraZeneca was attributed to large number of generic drugs entering the market. Eli Lilly has achieved a top position next to AstraZeneca and Sanofi-Aventis due to exceptional sales performance of its key product Alimta.

High Level Analysis

The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global lung cancer therapeutics market, their operating strategies, new launches, pipeline therapies and clinical trials. Porter’s five forces analysis has been used to determine the attractiveness of global lung cancer therapeutics market. Chemotherapy and radiation therapy shows large number of side effects and many a times need to be followed by surgery. Hence, constant demand for safe and efficacious therapeutics and improved technology is responsible to increase the bargaining power of suppliers. Large number of generic drugs is entering the market and therefore, the threat of substitute products tends to be high. To fulfill the demand for safe and effective drug therapy, many companies are putting their effort to pipeline research. Thus, it led to commercialization of large number of products and due to which rivalry is intense among participants.


  • This report offers the following benefits in particular:
  • Comprehensive coverage of global lung cancer therapeutics market along with disease overview, market trends, drivers and restraints
  • Through attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities, would be beneficial to understand the future market trends
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global lung cancer therapeutics market


The global lung cancer therapeutics market is segmented into two major categories such as, therapeutics and geography.


  • Chemotherapy
  • Taxotere
  • Hycamtin
  • Navelbine
  • Gemzar
  • Alimta
  • Targeted therapy
  • Tarceva
  • Iressa
  • Avastin
  • Pipeline drugs
  • Talactoferrin
  • Dacomitinib
  • Afatinib
  • Erbitux
  • ARQ 197
  • Ramucirumab
  • Surgery
  • Pneumectomy (Removal of whole lung)
  • Bilobectomy (Removal both lobes)
  • Lobectomy (removal of one lobe)
  • Radiotherapy


  • North America
  • Europe
  • Asia-Pacific

About Custom Market Insights:

Custom Market Insights is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive.

What makes us different from our competitors?

Compared to our competitors, our offerings include, but are not limited to market research services on latest industry trends, customized study at reasonable price, and database bigger than our competitors and provide more relevant results to fit your needs.

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
United States
Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.